Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2020
accepted:
22
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and did not respond to nintedanib. This study retrospectively examined the clinicoradiopathologic features of 40 consecutive patients with surgical lung biopsy-confirmed idiopathic pulmonary fibrosis treated with nintedanib. Additionally, we compared the histopathologic scoring of 21 microscopic features between patients with functional or radiological progression and those with non-progression during 12 months of treatment. The histopathologic evaluation showed edematous changes in the interlobular septum as the only histologic finding observed more frequently in patients with both functional and radiological progression than in those without (58% vs. 14%, P = 0.007 and 50% vs. 0%, P = 0.003, respectively). Regarding per-year change, patients with edematous changes in the interlobular septum showed greater progression in median changes in spared area (-12%, interquartile range: [-25%--5%], vs. -3% [-7%-0%], P = 0.004) and reticular shadow (7% [3%-13%], vs. 0% [0%-5%], P = 0.041) on computed tomography. Functional and radiological progression-free survival were shorter in patients with edematous changes in the interlobular septum than in those without (6.6 months, 95% confidence interval: [5.9-25.3], vs. event <50%, [12.1-Not available], P = 0.0009, and 6.1 months, [5.2-6.6] vs. 14.5 months [7.8-not available], P<0.0001). Edematous changes in the interlobular septum may indicate poor nintedanib efficacy in idiopathic pulmonary fibrosis. Further studies are needed to validate these findings and address the mechanism behind ECIS.
Sections du résumé
BACKGROUND
Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and did not respond to nintedanib.
METHODS
This study retrospectively examined the clinicoradiopathologic features of 40 consecutive patients with surgical lung biopsy-confirmed idiopathic pulmonary fibrosis treated with nintedanib. Additionally, we compared the histopathologic scoring of 21 microscopic features between patients with functional or radiological progression and those with non-progression during 12 months of treatment.
RESULTS
The histopathologic evaluation showed edematous changes in the interlobular septum as the only histologic finding observed more frequently in patients with both functional and radiological progression than in those without (58% vs. 14%, P = 0.007 and 50% vs. 0%, P = 0.003, respectively). Regarding per-year change, patients with edematous changes in the interlobular septum showed greater progression in median changes in spared area (-12%, interquartile range: [-25%--5%], vs. -3% [-7%-0%], P = 0.004) and reticular shadow (7% [3%-13%], vs. 0% [0%-5%], P = 0.041) on computed tomography. Functional and radiological progression-free survival were shorter in patients with edematous changes in the interlobular septum than in those without (6.6 months, 95% confidence interval: [5.9-25.3], vs. event <50%, [12.1-Not available], P = 0.0009, and 6.1 months, [5.2-6.6] vs. 14.5 months [7.8-not available], P<0.0001).
CONCLUSIONS
Edematous changes in the interlobular septum may indicate poor nintedanib efficacy in idiopathic pulmonary fibrosis. Further studies are needed to validate these findings and address the mechanism behind ECIS.
Identifiants
pubmed: 33411718
doi: 10.1371/journal.pone.0245147
pii: PONE-D-20-34933
pmc: PMC7790243
doi:
Substances chimiques
Indoles
0
nintedanib
G6HRD2P839
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245147Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Pulm Med. 2015 Apr 18;15:37
pubmed: 25927225
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Respir Med. 2005 Nov;99(11):1425-30
pubmed: 16210097
Front Med (Lausanne). 2017 Sep 25;4:154
pubmed: 28993806
Lancet Respir Med. 2018 Jul;6(7):554-565
pubmed: 29397349
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Inhal Toxicol. 2016 Aug;28(9):421-8
pubmed: 27308969
Eur Respir J. 2016 May;47(5):1518-34
pubmed: 27009171
Eur Respir Rev. 2017 Apr 26;26(144):
pubmed: 28446599
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Chest. 2018 Jun;153(6):1416-1423
pubmed: 29608882
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Natl Med Assoc. 1977 Mar;69(3):179-82
pubmed: 875070
Respir Med. 2016 Apr;113:74-9
pubmed: 26915984
BMJ Open Respir Res. 2018 Aug 20;5(1):e000325
pubmed: 30167310
Am J Respir Crit Care Med. 2001 Sep 15;164(6):1025-32
pubmed: 11587991
Am J Respir Crit Care Med. 2002 Jul 15;166(2):173-7
pubmed: 12119229
J Thorac Dis. 2018 Feb;10(2):899-908
pubmed: 29607163
Eur Respir J. 2019 May 18;53(5):
pubmed: 30880283
Chest. 2016 Mar;149(3):756-66
pubmed: 26836914
Thorax. 2006 Dec;61(12):1091-5
pubmed: 16769713
Eur Respir J. 2008 Mar;31(3):585-91
pubmed: 18057059
Proc Am Thorac Soc. 2006 Jun;3(4):285-92
pubmed: 16738191
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Eur Respir Rev. 2012 Dec 1;21(126):355-61
pubmed: 23204124
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Arch Pathol Lab Med. 2016 Dec;140(12):1375-1382
pubmed: 27610646
Lancet. 1976 Feb 28;1(7957):494
pubmed: 55771
N Engl J Med. 2018 Aug 23;379(8):797-798
pubmed: 30134133